[go: up one dir, main page]

NO20064151L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20064151L
NO20064151L NO20064151A NO20064151A NO20064151L NO 20064151 L NO20064151 L NO 20064151L NO 20064151 A NO20064151 A NO 20064151A NO 20064151 A NO20064151 A NO 20064151A NO 20064151 L NO20064151 L NO 20064151L
Authority
NO
Norway
Prior art keywords
treatment
active compounds
derivatives
alkyl
new connections
Prior art date
Application number
NO20064151A
Other languages
English (en)
Other versions
NO337281B1 (no
Inventor
Ivan Leo Pinto
Shahzad Sharooq
Neville Hubert Nicholson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20064151L publication Critical patent/NO20064151L/no
Publication of NO337281B1 publication Critical patent/NO337281B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer farmasøytisk aktive forbindelser som er xantinderivater, fremgangsmåter for fremstilling av nevnte derivater, farmasøytiske formuleringer som inneholder de aktive forbindelsene og anvendelse av forbindelsene ved behandling, særlig ved behandling av sykdommer hvor underaktivering av HM74A reseptoren bidrar til sykdommen eller hvor aktivering av reseptoren vil være fordelaktig, som har formel (II); hvori R' er valgt fra: hydrogen og C_alkyl som eventuelt kan være substituert med en eller flere grupper valgt fra CN og CF, Rer valgt fra: C-io usubstituert alkyl, Calkyl substituert med en eller flere grupper valgt fra fluor og CN, Calkenyl, uforgrenet Calkenyl og C^ alkyl substituert med cykloalkyl og Rer valgt fra halogen og CN.
NO20064151A 2004-02-14 2006-09-13 Nye forbindelser, anvendelse derav for fremstilling av et medikament, farmasøytisk formulering og kombinasjon NO337281B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Publications (2)

Publication Number Publication Date
NO20064151L true NO20064151L (no) 2006-11-06
NO337281B1 NO337281B1 (no) 2016-02-29

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064151A NO337281B1 (no) 2004-02-14 2006-09-13 Nye forbindelser, anvendelse derav for fremstilling av et medikament, farmasøytisk formulering og kombinasjon

Country Status (25)

Country Link
US (5) US7713982B2 (no)
EP (1) EP1781657B1 (no)
JP (2) JP5001012B2 (no)
KR (1) KR101100601B1 (no)
CN (2) CN101863888B (no)
AR (1) AR047669A1 (no)
AU (1) AU2005212816C1 (no)
BR (1) BRPI0507604A (no)
CA (1) CA2556073C (no)
CY (1) CY1114022T1 (no)
DK (1) DK1781657T3 (no)
ES (1) ES2406732T3 (no)
HR (1) HRP20130406T1 (no)
IL (1) IL177051A (no)
MA (1) MA28357A1 (no)
MY (1) MY148937A (no)
NO (1) NO337281B1 (no)
NZ (1) NZ548496A (no)
PE (1) PE20060317A1 (no)
PL (1) PL1781657T3 (no)
PT (1) PT1781657E (no)
SG (1) SG157242A1 (no)
SI (1) SI1781657T1 (no)
TW (1) TWI350289B (no)
WO (1) WO2005077950A2 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527917A (en) * 1999-11-12 2005-03-24 Biogen Inc Polycycoalkylpurines as adenosine receptor antagonists
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7713982B2 (en) * 2004-02-14 2010-05-11 Smithkline Beecham Corporation Xanthines with HM74A receptor activity
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006124490A2 (en) 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006134040A1 (en) * 2005-06-14 2006-12-21 F. Hoffmann-La Roche Ag Anthranilic acid derivatives
KR20080019653A (ko) 2005-06-28 2008-03-04 머크 앤드 캄파니 인코포레이티드 나이아신 수용체 효능제, 이를 함유하는 조성물 및치료방법
MX2008001931A (es) * 2005-08-10 2008-03-24 Smithkline Beecham Corp Derivados de xantina como agonistas selectivos de hm74a.
WO2007087204A2 (en) * 2006-01-20 2007-08-02 Schering Corpooration Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
ATE469905T1 (de) * 2006-05-23 2010-06-15 Hoffmann La Roche Pyridopyrimidinonderivate
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
AR061625A1 (es) * 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
US7462624B2 (en) 2006-06-23 2008-12-09 Incyte Corporation Purinone derivatives as HM74a agonists
KR101115891B1 (ko) * 2007-03-23 2012-02-13 에프. 호프만-라 로슈 아게 아자-피리도피리미딘온 유도체
BRPI0922134A2 (pt) * 2008-12-08 2015-08-18 Glaxosmithkline Llc Compostos
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
WO2016119570A1 (zh) * 2015-01-30 2016-08-04 上海珊顿医药科技有限公司 尿酸性或痛风性疾病的预防或治疗
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（二）
EP4034101A1 (en) * 2019-09-25 2022-08-03 Goldfinch Bio, Inc. Xanthine cb1 inhibitors
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
AU2024229006A1 (en) * 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
AU3725893A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
WO1993017684A2 (en) 1992-03-04 1993-09-16 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
CA2183562A1 (en) * 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CA2369981A1 (en) 1999-04-09 2000-10-19 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
HK1049835B (zh) * 1999-08-31 2005-04-08 范德比尔特大学 A2b腺苷受体的选择性拮抗剂
US6855817B2 (en) * 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
WO2002024194A2 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
MXPA03007349A (es) 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
AU2002242910A1 (en) * 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
US7713982B2 (en) 2004-02-14 2010-05-11 Smithkline Beecham Corporation Xanthines with HM74A receptor activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
MX2008001931A (es) * 2005-08-10 2008-03-24 Smithkline Beecham Corp Derivados de xantina como agonistas selectivos de hm74a.
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
BRPI0922134A2 (pt) * 2008-12-08 2015-08-18 Glaxosmithkline Llc Compostos
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
AR047669A1 (es) 2006-02-01
MA28357A1 (fr) 2006-12-01
PL1781657T3 (pl) 2013-08-30
PE20060317A1 (es) 2006-06-22
US8268839B2 (en) 2012-09-18
CA2556073A1 (en) 2005-08-25
HK1104530A1 (en) 2008-01-18
US20130150383A1 (en) 2013-06-13
CA2556073C (en) 2012-01-10
DK1781657T3 (da) 2013-06-10
US20100010021A1 (en) 2010-01-14
CN101863888A (zh) 2010-10-20
HRP20130406T1 (hr) 2013-06-30
US7713982B2 (en) 2010-05-11
AU2005212816B2 (en) 2009-07-23
TWI350289B (en) 2011-10-11
JP5001012B2 (ja) 2012-08-15
IL177051A0 (en) 2006-12-10
JP5020848B2 (ja) 2012-09-05
WO2005077950A3 (en) 2007-04-19
ES2406732T3 (es) 2013-06-07
SG157242A1 (en) 2009-12-29
TW200536537A (en) 2005-11-16
AU2005212816C1 (en) 2010-03-04
JP2007522176A (ja) 2007-08-09
NO337281B1 (no) 2016-02-29
CN101103030A (zh) 2008-01-09
CN101103030B (zh) 2010-10-13
WO2005077950A2 (en) 2005-08-25
AU2005212816A1 (en) 2005-08-25
US20150080418A1 (en) 2015-03-19
BRPI0507604A (pt) 2007-07-03
CY1114022T1 (el) 2016-07-27
US20070135456A1 (en) 2007-06-14
KR20060126772A (ko) 2006-12-08
KR101100601B1 (ko) 2011-12-29
EP1781657B1 (en) 2013-03-27
PT1781657E (pt) 2013-05-23
SI1781657T1 (sl) 2013-07-31
CN101863888B (zh) 2012-07-18
IL177051A (en) 2013-01-31
JP2008120831A (ja) 2008-05-29
US8394808B2 (en) 2013-03-12
US20100160354A1 (en) 2010-06-24
MY148937A (en) 2013-06-14
NZ548496A (en) 2010-02-26
EP1781657A2 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
NO20064151L (no) Nye forbindelser
CN104837825B (zh) 鲁顿酪氨酸激酶抑制剂
CA2954751C (en) Indoles for use in influenza virus infection
ES2977656T3 (es) Inhibidores de KDM1A para el tratamiento de enfermedades
CN113950471B (zh) 带电的离子通道阻滞剂及其使用方法
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20092342L (no) Azaspiroderivativater
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20090327L (no) Nye forbindelser 384
NO20081844L (no) Terapeutiske forbindelser
CN106879256B (zh) 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20082496L (no) Pyrazinderivater
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20071314L (no) Peptidiske vasopressinreseptoragonister
CN106795137B (zh) 氮杂环丁烷基氧基苯基吡咯烷化合物

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE LLC, US

MM1K Lapsed by not paying the annual fees